<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The underlying defects in <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome (AS)</z:e> and <z:hpo ids='HP_0000729'>autism spectrum disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>) may be in part due to basic defects in synaptic plasticity and function </plain></SENT>
<SENT sid="1" pm="."><plain>In some individuals <z:chebi fb="19" ids="28790">serotonin</z:chebi> reuptake inhibitors, which decrease pre-synaptic re-uptake of <z:chebi fb="19" ids="28790">serotonin</z:chebi>, can ameliorate symptoms, as can resperidone, which blocks both <z:chebi fb="40" ids="18243">dopamine</z:chebi> and <z:chebi fb="19" ids="28790">serotonin</z:chebi> receptors </plain></SENT>
<SENT sid="2" pm="."><plain>Loss of maternal UBE3A expression causes AS, while maternal duplications of chromosome 15q11.2-q13 that include the UBE3A gene cause <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>, implicating the maternally expressed UBE3A gene in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> phenotype </plain></SENT>
<SENT sid="3" pm="."><plain>In a Drosophila screen for proteins regulated by UBE3A, we identified a key regulator of <z:chebi fb="3" ids="25375">monoamine</z:chebi> synthesis, the gene Punch, or GCH1, encoding the enzyme <z:chebi fb="11" ids="15996">GTP</z:chebi> cyclohydrolase I </plain></SENT>
<SENT sid="4" pm="."><plain>Here we show that Dube3a, the fly UBE3A orthologue, regulates Punch/GCH1 in the fly brain </plain></SENT>
<SENT sid="5" pm="."><plain>Over-expression of Dube3a elevates tetrahydrobiopterin (THB), the rate-limiting cofactor in <z:chebi fb="3" ids="25375">monoamine</z:chebi> synthesis while loss of Dube3a has the opposite effect </plain></SENT>
<SENT sid="6" pm="."><plain>The fluctuations in <z:chebi fb="40" ids="18243">dopamine</z:chebi> levels were associated with hyper- and <z:mp ids='MP_0001402'>hypoactivity</z:mp>, respectively, in flies </plain></SENT>
<SENT sid="7" pm="."><plain>We show that changes in Punch/GCH1 and <z:chebi fb="40" ids="18243">dopamine</z:chebi> levels do not depend on the ubiquitin ligase catalytic domain of Dube3a </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, both <z:mp ids='MP_0002169'>wild type</z:mp> Dube3a and a ubiquitination-defective Dube3a-C/A form were found at high levels in nuclear fractions and appear to be poly-ubiquitinated in vivo by endogenous Dube3a </plain></SENT>
<SENT sid="9" pm="."><plain>We propose that the transcriptional co-activation function of Dube3a may regulate GCH1 activity in the brain </plain></SENT>
<SENT sid="10" pm="."><plain>These results provide a connection between <z:chebi fb="3" ids="25375">monoamine</z:chebi> synthesis (<z:chebi fb="40" ids="18243">dopamine</z:chebi>/<z:chebi fb="19" ids="28790">serotonin</z:chebi>) and Dube3a expression that may explain why some individuals with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> or AS respond better to selective <z:chebi fb="19" ids="28790">serotonin</z:chebi> reuptake inhibitors than others </plain></SENT>
</text></document>